You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
21 July 2026 - India-based global pharmaceutical company Lupin Limited (BSE: 500257) (NSE: LUPIN) announced on Tuesday the strategic spin-out of two oncology programmes, LNP7457 (PRMT5) and LNP8701 (SOS1), through its wholly owned subsidiary, Lupin I...
21 July 2026 - Fuse Oncology, a structured AI platform for radiation oncology, announced on Monday the launch of FuseRx, a prescribing and treatment-intent solution for radiation oncology.According to Fuse Oncology, FuseRx is the keystone of the Fuse...
21 July 2026 - Clinical-stage biopharmaceutical company AbelZeta Pharma Inc announced on Monday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted PRIority MEdicines (PRIME) designation f...
20 July 2026 - Personalis Inc (Nasdaq: PSNL), a provider of advanced genomics for precision oncology, announced on Monday that it has agreed to be acquired by technology firm Tempus AI Inc (NASDAQ: TEM) in a transaction valued at approximately USD1.5...
20 July 2026 - Biotechnology company Sareum Holdings plc (AIM: SAR) announced on Monday that it has completed dosing in the Phase 2-enabling toxicology programme for SDC-1801, its selective oral TYK2/JAK1 inhibitor being developed for autoimmune dise...
20 July 2026 - Evaxion A/S, a Denmark-based, clinical-stage TechBio company developing novel vaccines with its AI-Immunology platform, said on Friday that it will present three-year clinical efficacy data from its phase 2 trial with personalised canc...
20 July 2026 - Canada-based biotechnology company Arch Biopartners Inc (TSX-V:ARCH) (OTCQB:ACHFF) announced on Friday that it has engaged a US-based laboratory specialising in bioengineering to accelerate the company's pre-IND IL-32 chronic kidn...